Precision Oncology Alliance

Caris Life Sciences® founded the Precision Oncology Alliance™ (POA) to promote the study and appropriate use of molecular testing in the diagnosis and treatment of cancer.​

Precision Oncology Alliance

The Caris Precision Oncology Alliance™ (POA) convenes the brightest minds in oncology, cancer care, clinical research, and drug development. The vision statement of the POA is to build the best-in-class collaborative research network focusing on precision oncology to identify predictive and prognostic markers that help in improving the outcomes and clinical care of patients with cancer. The POA aims to deliver molecular science solutions to promote clinical trials that cultivate combined clinical-genomic data and collaborative research to advance the science of cancer care. The alliance is comprised of a growing network of leading cancer centers from across the country that demonstrate a commitment to precision medicine and work collaboratively to:

  • Integrate molecular testing where appropriate into cancer care and patient treatment management
  • Collaborate on research studies and clinical trials
  • Track longitudinal clinical outcomes, contribute data, and correlate outcomes with molecular clinical demographic attributes
  • Publish innovative abstracts and manuscripts in top-tier journals promoting academic advancement in molecular profiling and its impact on clinical care

It’s important for oncologists and patients to know that their data is available to them for analysis. Our database of clinical outcomes is populated with anonymized data from POA member institutions and from commercially available data. This continuous feedback loop between finding new biomarkers and interpreting their significance, provides insights for drug developers, which ultimately feeds back into our system and directly helps patients.

icon_quotes.png

The Caris Precision Oncology Alliance™ is focused on collecting the latest scientific developments in genomics in order to help ensure the availability of individualized data to oncologists and patients and to further advance the integration of molecular profiling into all aspects of cancer care .”

Chadi Nabhan, MD, MBA, FACP
Chairman
Precision Oncology Alliance

Chadi Nabhan, MD | Chairman, Precision Oncology Alliance

In addition to creating a thought leadership network to develop best practices and guidelines for integrating molecular profiling into patient treatment management, POA members:

  • Utilize the Caris Molecular Intelligence® platform to identify therapy options and clinical trial opportunities based on the unique molecular characteristics of a patient’s tumor.
  • Contribute to the Caris database. We are increasingly able to link to their electronic medical records to augment their clinical outcomes data with our molecular data in a user interface that allows analysis of the combined data set.
  • Leverage the network to conduct research and to generate and publish clinical outcomes data.
  • Leverage available data to participate in pharma-sponsored precision oncology research studies and enhance the ability to efficiently conduct investigator-initiated trials.
  • Explore cost-effectiveness studies and analyses leveraging Caris data.
  • Partner with payors and regulatory bodies to establish value-based reimbursement.

POA Leadership

Executive Committee
The Caris Precision Oncology Alliance™ (POA) Executive Committee establishes appropriate molecular testing principles to serve as guidelines for the consistent application of tumor profiling across the oncology community. The Executive Committee facilitates collaborative research studies across the POA and coordinates outcome tracking initiatives to generate and document additional medical evidence for the appropriate use and impact of profiling. The Executive Committee of the POA serves as a resource to Caris leadership helping to drive research strategy and direction.

Chadi Nabhan, MD, MBA, FACP

Chairman
Precision Oncology Alliance

John L. Marshall, MD

Chief, Hematology and Oncology
Georgetown University

Elisabeth Heath, MD

Associate Center
Director Translational Sciences
Karmanos Cancer Institute

Heinz-Josef Lenz, MD, FACP

Associate Director for Clinical Research
USC Norris Comprehensive Cancer Center

Thomas Herzog, MD

Professor of OB-GYN
Deputy Director
University of Cincinnati Cancer Institute

Wafik El-Deiry, MD, PhD, FACP

Associate Dean for Oncologic Sciences
Brown University

Marcia Cruz-Correa, MD, PhD

Associate Professor
University of Puerto Rico

Ruben Mesa, MD

Director
UT Health San Antonio
MD Anderson Center

Sagar Lonial, MD, FACP

Chief Medical Officer
Professor and Chair
Emory University

Joann Sweasy, PhD

Director, Cancer Center
Associate Director, Basic Sciences
University of Arizona

POA Working Groups
The POA Working Groups identify leadership opportunities, author publications, and develop protocols.

Virginia_Kaklamani_Round
Breast
Virginia Kaklamani, MD
Professor of Medicine
University of Texas San Antonio
Ashley_Sumrall_Round
Central Nervous System
Ashley Sumrall, MD, FACP
Section Chief, Neuro-oncology
Levine Cancer Institute
April_Salama_Round
Cutaneous Oncology

April Salama, MD
Associate Professor of Medicine
Duke Cancer Institute

Emil_Lou_Round
Gastrointestinal
Emil Lu, MD, PhD, FACP
Associate Professor of Medicine
University of Minnesota
Charles_Ryan_Round
Genitourinary

Charles Ryan, MD
Professor of Medicine
University of Minnesota

Global Oncology
Gilberto Lopes, MD
Associate Director, Global Oncology
University of Miami
Premal_Thaker_Round
Gynecologic

Premal Thaker, MD, MS
Professor of OB-GYN
Washington University

Tricia_Wise-Draper_Round
Head and Neck

Trisha Wise-Draper, MD, PhD
Associate Professor of Medicine
University of Cincinnati

Leukemia
Jay Yang, MD
Assistant Professor, Clinical
Karmanos Cancer Institute
Evens_Round
Lymphoma

Andrew Evens, DO, MSc
Director, Lymphoma Program
Rutgers Cancer Institute

Usmani_Round
Myeloma

Saad Z. Usmani, MD, FACP
Division Chief, Plasma Cell Disorders Division
Levine Cancer Institute

Heloisa-Soares
Neuroendocrine

Heloisa Soares, MD, PhD
Assistant Professor
Huntsman Cancer Institute

POA_Headshot_Dahiya
Pathology

Sonika Dahiya, MD
Professor, Pathology & Immunology
Washington University

Valerie Brown, MD, PhD
Pediatrics/AYA
Valerie Brown, MD, PhD
Professor, Department of Pediatrics
Penn State University
Sarcoma
Jonathan Trent, MD, PhD
Professor
University of Miami
Liu_Round
Thoracic
Stephen Liu, MD
Associate Professor of Medicine
Georgetown University
Translational

Wafik El-Deiry, MD, PhD, FACP
Associate Dean
Brown University

POA Pathology Group

POA_Headshot_Dahiya
Chair

Sonika Dahiya, MD
Professor, Pathology and Immunology
Washington University

POA_Headshot_Wang
Breast

Yihong Wang, MD, PhD
Associate Professor of Path. & Lab. Medicine
Brown University

POA_Headshot_Lopez
Central Nervous System

Giselle Y. Lopez, MD, PhD
Assistant Professor, Pathology
Duke University

POA_Headshot_Phung
Cutaneous

Thuy Phung, MD, PhD
Associate Professor of Pathology
University of South Alabama

POA_Headshot_Yakerevich
Gastrointestinal

Evgeny Yakirevich, MD   
Professor, Path. & Lab. Medicine
Brown University

POA_Headshot_Wei
Genitourinary

Sam Wei, MD, PhD     
Associate Professor, Pathology
Fox Chase Cancer Center

POA_Headshot_Fehmi
Gynecologic

Rouba Ali-Fehmi, MD
Professor
Karmanos Cancer Institute

POA_Headshot_Weinberg_2
Hematopathology

Olga Weinberg, MD
Associate Professor, Pathlogy
UT Southwestern

POA_Headshot_Chernock
Head & Neck

Rebecca Chernock, MD     
Associate Professor, Path & Immun.
Washington University

Kajsa-Affolter
Neuroendocrine

Kajsa Affolter, MD
Assistant Professor, Pathology
Huntsman Cancer Institute

POA_Headshot_Rosenberg
Sarcoma

Andrew E. Rosenberg, MD 
Professor, Vice Chair, Director, Pathology
University of Miami

POA_Headshot_Dacic
Thoracic

Sanja Dacic, MD, Phd 
Professor of Pathology
University of Pittsburgh Medical Center

POA_Headshot_Braxton
Translational

David Braxton, MD
Molecular Genetic Pathologist
Hoag

POA Members

The Caris Precision Oncology Alliance™ consists of leading cancer centers around the world that are committed to precision medicine and work collaboratively to advance the delivery of molecular testing and establish standards of care for profiling solid tumors.

POA Publications

Every day, new discoveries confirm the increasing and important role biomarker analysis and tumor profiling have in personalized cancer care. We contribute to the body of research in oncology to advance the understanding of molecular science and further enable the delivery of precision medicine.

POA Newsletter

The Caris Connection e-newsletter is a quarterly publication for all POA members. Each issue highlights a POA member institution, an interview with a key investigator, and the latest news and events happening throughout our alliance. Members can also find updates on the Caris pipeline, the latest POA publications and abstracts, and register for any one of the many Working Group Sessions that take place throughout the year.
Need Support?
Contact Us
or call 1.888.979.8669 (international: +41 21 533 53 00)